Featured articles from the journal CHEST®, December 2022
Glenview, Illnois | 2022년 12월 15일
Published monthly, the journal CHESTopens in new tab/window® features peer-reviewed, cutting-edge original research in chest medicine: Pulmonary, critical care and sleep medicine and related disciplines. Journal topics include asthma, chest infections, COPD, critical care, diffuse lung disease, education and clinical practice, pulmonary vascular disease, sleep, thoracic oncology and the humanities.
The December issueopens in new tab/window of CHEST contains 36 articles, including clinically relevant research, reviews, case series, commentary and more. Each month, the journal also offers complementary web and multimedia activitiesopens in new tab/window, including visual abstracts, to expand the reach of its most interesting, timely and relevant research.
“Well-suited for the final issue of 2022, the December issue of the journal CHEST includes articles that look back at lessons learned from the COVID-19 pandemic and insights into planning for future surges,” says Editor-in-Chief of the journal CHEST, Peter Mazzone, MD, MPH, FCCP. “’COVID-19: Lessons Learned, Lessons Unlearned, Lessons for the Futureopens in new tab/window’ was written by editorial board members for the critical care section of the journal CHEST and ‘A Regional Command Center for Pandemic Surgeopens in new tab/window’ is a prospective observational study conducted in Catalonia from March 15, 2020, to July 1, 2021.”
Also included in the current issue of the journal CHEST:
Chest Infections
Recommending constant microbiological surveillance, “Multidrug-Resistant and Extended-Spectrum β-Lactamase Gram-Negative Bacteria in Bilateral Lung Transplant Recipientsopens in new tab/window” discourages the use of empirical broad-spectrum antibiotics.
Critical Care
A large, multicenter retrospective study, “Inhaled Nitric Oxide vs Epoprostenol During Acute Respiratory Failureopens in new tab/window” finds large variation in the use of inhaled nitric oxide and inhaled epoprostenol during acute respiratory failure across the United States. A visual abstract for the research can be viewed hereopens in new tab/window.
Diffuse Lung Disease
Looking at patients with lymphangioleiomyomatosis, “Impact of Age, Menopause, and Sirolimus on Spontaneous Pneumothoraces in Lymphangioleiomyomatosisopens in new tab/window” research finds increasing age and menopausal status are associated with a reduced risk of development of spontaneous pneumothoraces (SP), and the use of mechanistic target of rapamycin inhibitors is associated with reduced recurrence risk of SP. A visual abstract for the research can be viewed hereopens in new tab/window.

What Is the Impact of Age, Menopausal Status, and Sirolimus on Spontaneous Pneumothorax in Lymphangioleiomyomatosis? (Credit: Noella Cortinas, MD, et al. CHEST December 2022, https://doi.org/10.1016/j.chest.2022.05.036opens in new tab/window).
Thoracic Oncology
The largest study to date on the topic, “Bleeding Risk With Combination Intrapleural Fibrinolytic and Enzyme Therapy in Pleural Infectionopens in new tab/window” shows that, aside from specific scenarios, safety or risk of bleeding alone should no longer be a deterrent to the use of intrapleural fibrinolytic and enzyme therapy in pleural infection. A visual abstract for the research can be viewed hereopens in new tab/window.
---
Notes for editors
To view the entire December issue of CHEST journal (volume 162, issue 6), published by Elsevier, visit journal.chestnet.orgopens in new tab/window and follow @journal_CHESTopens in new tab/window on Twitter for the latest journal news.
Full text of these articles and interviews with the authors are available to credentialed journalists upon request; contact Laura DiMasi, PR and Communications Specialist, American College of Chest Physicians (CHEST), at [email protected]opens in new tab/window.
About the journal CHEST®
The journal CHESTopens in new tab/window, the official publication of the American College of Chest Physicians®, features the best in peer-reviewed, cutting-edge original research in the multidisciplinary specialties of chest medicine: pulmonary, critical care, and sleep medicine; thoracic surgery; cardiorespiratory interactions; and related disciplines. Published since 1935, it is home to the highly regarded clinical practice guidelines and consensus statements. Access the journal CHEST online at journal.chestnet.orgopens in new tab/window.
About the American College of Chest Physicians
The American College of Chest Physicians® (CHEST) is the global leader in the prevention, diagnosis, and treatment of chest diseases. Its mission is to champion advanced clinical practice, education, communication, and research in chest medicine. It serves as an essential connection to clinical knowledge and resources for its 19,000+ members from around the world who provide patient care in pulmonary, critical care and sleep medicine. For information about the American College of Chest Physicians, and its flagship journal CHEST®, visit chestnet.org.opens in new tab/window
엘스비어 소개
엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업으로 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔습니다. 우리는 170개국 이상에서 학술 및 기업 연구 커뮤니티, 의사, 간호사, 미래의 의료 전문가와 교육자들을 지원합니다. 근거에 기반한 신뢰할 수 있는 과학·의학 콘텐츠와 최첨단 AI 기술을 결합해 중요한 통찰과 혁신적인 솔루션을 제공해, 의미있는 성과를 이루도록 돕고 있습니다. 또한 다양성과 지속 가능성을 제품과 기업 문화 전반에 내재화하며, 우리가 속한 커뮤니티와 협력합니다. 엘스비어 재단opens in new tab/window은 전 세계에서 연구와 보건 파트너십을 지원합니다.
엘스비어는 전문가 및 기업 고객에게 정보 기반의 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원입니다. 자세한 내용은 www.elsevier.com에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아보실 수 있습니다.
연락처
LD
Laura DiMasi
PR and Communications Specialist
American College of Chest Physicians (CHEST)
Laura DiMasi 이메일